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Abstract
NIH-PA Author Manuscript

Recent advances in radiotherapy have enabled the use of different types of particles, such as
protons and heavy ions, as well as refinements to the treatment of tumours with standard sources
(photons). However, the risk of second cancers arising in long-term survivors continues to be a
problem. The long-term risks from treatments such as particle therapy have not yet been
determined and are unlikely to become apparent for many years. Therefore, there is a need to
develop risk assessments based on our current knowledge of radiation-induced carcinogenesis.

NIH-PA Author Manuscript

Advances in paediatric cancer care have yielded steady gains in survival time over the past
four decades. Today, in the United States, approximately 80% of children with cancer will
survive 5 years or longer, compared with 30% in 1960 (REF. 1). Epidemiological studies of
survivors of childhood cancer revealed startling rates of disease and treatment-related health
problems2. Survivors experience an alarmingly high incidence of chronic health problems
after their treatment3, including second primary cancers, cardiac toxicity and fertility
problems, to name just a few4. This means that survivors experience more than an extra
decade of ill health compared with children who have not been treated for cancer. Long-term
survivors of childhood cancer who received radiotherapy are at a significantly increased risk
for the development of second malignant neoplasms (SMNs)2: the incidence of SMNs is
around 10–20% 30 years after treatment1. Indeed, the 5-year survival rate for children with
medulloblastoma is 73%1, but the 30-year cumulative incidence of SMNs is 31%2.
Reducing the risk of second cancers in survivors of childhood cancer will require the
identification of patients at the greatest risk for SMNs5,6, improved treatment regimens7 and
improved health care for adult survivors within the economic constraints that are placed on
the health care system8. Research into cancer survival aims to better understand, prevent and
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treat late-occurring effects in long-term survivors while preserving the high rates of local
control and long-term survival that are achieved with contemporary treatments7.
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The path forwards presents challenges to researchers, policy makers and clinicians. Various
approaches have been proposed to reduce the incidence of SMNs from radiotherapy, mainly
by reducing radiation doses to healthy tissues by using new techniques and various types of
radiation, such as protons or heavy ions. However, few clinical comparative effectiveness
studies have been conducted9, and no long-term epidemiological studies of SMN incidence
following proton or carbon therapies yet exist. Significant outcome-based evidence on SMN
risk will not be forthcoming for many years as SMNs generally take a long time to develop.
Moreover, it is currently unclear what these outcome data are likely to show or whether they
will have much effect on the decision to use particle therapy as a mode of cancer treatment,
as refinements are likely to be ongoing in this rapidly developing technological area.
Therefore, decisions will have to be made using alternative types of evidence, as is
customary and common in many other rapidly advancing disciplines of medicine. The
evidence will by necessity comprise theoretical predictions.

NIH-PA Author Manuscript

There are compelling theoretical advantages for particle therapy10,11 compared with
conventional X-ray treatment. The advantage of charged particles derives mainly from their
ability to simultaneously deliver a large dose to the tumour while mostly sparing
surrounding healthy tissues10. Some researchers rightly caution that the existing knowledge
and understanding of SMN induction is not sufficiently complete to justify the use of some
advanced radiotherapies for treating children12. Much of the controversy is related to the
carcinogenic risk from secondary neutrons, which are unavoidably present with particle
treatments13. Quantifying this risk requires detailed knowledge of an extensive array of
parameters. These dose and risk assessments are complex, expensive and require a multidisciplinary research team14.
The objective of this Review is to discuss recent advances in our understanding of the effect
of advanced radiotherapies on the risk of SMNs in survivors of childhood cancer.

Radiotherapy for paediatric patients
NIH-PA Author Manuscript

Detailed statistics on the risk of SMNs related to radiotherapy are difficult to obtain because
cancer in children is relatively rare. In children, lymphoma, leukaemia, brain tumours,
sarcomas, Wilm’s tumour, neuroblastoma and liver cancers are typically treated with
radiotherapy15. Paediatric patients with tumours in the central nervous system, skull base
and bone are those expected to benefit most from treatment with protons16 or carbon ions17.
Even though the number of patients treated is fairly small, data obtained so far suggest that
proton beam therapy can achieve better local control with no increase in acute toxicity for
many childhood solid tumours18.
Eric J. Hall12 addressed three major factors that contribute to an increased risk of SMNs in
children. First, the atomic bomb survivors database clearly shows that cancer risk depends
on the age at exposure and decreases from about 15% per unit dose equivalent (Sv−1) at
under 10 years of age to about 1% Sv−1 for adults exposed at over 60 years age (see BOX 1
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for the definition of dose and Sv). Second, the problem of genetic susceptibility is more
serious for children than for adults, in whom carcinogenesis is often associated with lifestyle
choices and environmental factors. Many cases of childhood cancer involve a germline
mutation, such as the hereditary form of retinoblastoma, and this raises the question of
whether the paediatric patient is also more sensitive and susceptible to radiation-induced
cancer. Finally, the issue of stray radiation is more serious for children than for adults,
simply because of the difference in body size12.
In its most recent report focused on SMNs, the Childhood Cancer Survivor Study (CCSS)
screened 14,359 survivors, and found 2,703 neoplasms1. Survivors of Hodgkin’s lymphoma
and Ewing’s sarcoma were those at highest SMN risk. A relationship between the relative
risk and the dose received for the treatment of the primary cancer could be established for
SMNs in the central nervous system, breast and thyroid. Gliomas generally occurred in the
high-dose region before an attained age of 30 years in patients who had previously been
treated for brain tumours, while breast cancers were observed in low-dose regions after the
patients were older than 30 years of age. Taken together, the dose–response relationships,
the relative risks and the latency periods for SMNs in the CCSS are consistent with what
was expected from the large database of atomic bomb survivors19.

NIH-PA Author Manuscript

Novel techniques in radiotherapy
In the past few years, enormous progress has been made in radiotherapy20–22, leading to the
possibility of providing escalating radiation doses (BOX 1) to the tumour while sparing the
normal surrounding tissue (FIG. 1). This rapid progress has been boosted by advances in
imaging tools to identify the tumour, in computerized treatment planning systems and in the
development of radiation treatment machines.

NIH-PA Author Manuscript

Contemporary radiotherapy techniques often produce photoneutrons or use accelerated
charged particles. Therefore, one of the most important issues is the influence of radiation
quality on carcinogenesis. The difference between sparsely and densely ionizing radiation is
in the initial energy deposition patterns. The relative biological effectiveness (RBE) of a
given radiation is related to the spatial density of energy deposition events, known as the
linear energy transfer (LET). A dose delivered by photons (sparsely ionizing or low-LET
radiation) is more uniformly distributed than an equal dose of heavy ions (densely ionizing
or high-LET radiation). Protons at high energy are similar to X-rays, but at low energy their
LET increases and their RBE is higher than α-particles at the same LET23. These lowenergy secondary protons are responsible for the high RBE of neutrons, arguably the most
effective particles in inducing late effects24.
For heavy ion therapy, target tissues are exposed to carbon ions, and distal organs to
neutrons and scattered protons10.
Photon therapy
Because of the unfavourable depth–dose distribution of X-rays, more than one photon beam
has to be used to increase the dose to the tumour while sparing the normal surrounding
tissue20. The improvements in computerized tomography (CT) imaging in the 1980s made it
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possible to switch to CT-based radiotherapy and three-dimension conformal radiotherapy
(3D-CRT). The ability to modulate the intensity of the different beams — intensitymodulated radiation therapy (IMRT) — yielded better target to normal tissue dose ratios (in
the moderate–high dose region) and improved sparing of important structures compared
with 3D-CRT25,26. When combined with image-guided radiotherapy (IGRT) technologies,
which take into account daily organ motions and tumour shrinkage, IMRT is the ‘state of the
art’ photon therapy27.
However, as first pointed out by Hall and Wuu28, the move from 3D-CRT to IMRT has a
cost: the risk of SMNs can increase, and may in fact be almost twofold higher. This is
essentially caused by two problems: IMRT requires many more fields from different angles
than conformal therapy, and therefore a larger volume of normal tissue is exposed to
radiation; the exposure of out-of-field tissues from leakage X-rays is also increased, because
IMRT requires twofold to threefold more monitor units to deliver a specified dose to the
target compared with 3D-CRT.
Particle therapy

NIH-PA Author Manuscript
NIH-PA Author Manuscript

In parallel to advances in photon therapy, radiotherapy with charged particles has evolved
substantially since it was originally proposed more than 60 years ago29. The rationale of
particle therapy is simple: unlike photons, charged particles deposit most of their energy
near the end of their range, in the region of the so-called Bragg peak. The Bragg peak is
spread out to cover the whole tumour volume, and the exit dose — the dose beyond the
tumour — is lower than with photon therapies. Particle therapy can therefore provide
excellent dose conformation to the target while simultaneously providing better sparing of
normal tissues10 (FIG. 1d). Heavy ions (such as carbon) provide physical advantages
compared with photon beams and have a radiobiological benefit. Although high-energy
protons have similar LET, and therefore RBE, as photons, carbon ions have low-LET in the
entrance region, where the normal tissue is exposed, but high-LET at the end of their range,
where the tumour is located30. Heavy-ion therapy is therefore preferable for radioresistant
cancers, such as sarcomas, renal cell carcinoma, melanoma and glioblastoma11. To treat
deep-seated tumours with heavy ions, complex treatment systems are required. The size and
cost of such systems are presently larger than those of photon therapy; new technologies and
economies of scale are expected to lead to smaller, less expensive systems within the next
few years.
Currently, more than 20 centres are actively treating patients, and over 70,000 cancer
patients have received particle therapy29. Most of these patients were treated with protons,
but the use of heavier ions is increasing10. The debate regarding the cost/benefit ratio of this
treatment is still ongoing9, but many more centres are currently under construction and the
number of cancer survivors, especially paediatric patients, treated with charged particles is
rapidly increasing10. These facts increase the urgency to better understand the risks of
SMNs: in fact, neutrons and heavy ions are more effective than photons in cancer
induction31.
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Potential risks of new techniques
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In the past few years, the concerns and controversy about the risk of SMNs following
particle therapy has reached unprecedented levels12,32. This controversy is related to the
high cost of the particle therapy facility and the debate regarding the cost/benefit ratio9, but
it is partly a consequence of a lack of reliable dose and risk assessments tools. Available
radiotherapy treatment planning systems do not provide accurate out-of-field dose
calculations far from the treatment target32–34. At present, only a few institutions have the
capability to carry out whole-body dose and risk assessments for conventional and advanced
radiotherapies32,35,36.

NIH-PA Author Manuscript

Leakage neutrons are a problem for both high-energy photon and charged-particle therapies
(FIG. 2a). In fact, photons at energies above 8–10 MV (depending on the target material)
produce neutrons by photonuclear reactions (FIG. 2b). High-energy photons provide a better
depth–dose distribution and are therefore preferred over lower energy X-rays for treating
deep-seated tumours. High-energy photons interact with materials in collimators and the
beam delivery system and can cause photonuclear reactions, which yields unwanted
neutrons that contribute to the SMN risk. Photoneutrons are major contributors to doses of
18 MV photons at distances >20 cm from the target32, and the dose tends to flatten rather
than decrease at greater distance. The patient is therefore immersed in a ‘neutron bath’
(FIGS 1b,2a).
With passive proton beam shaping, many neutrons are produced in the treatment unit32,37,
and it has been argued that the leakage of these neutrons may substantially increase the risk
of SMNs in distal organs13 (FIG. 2). Heavy ions also produce secondary particles by nuclear
fragmentation, and these particles can deposit their energy in the normal tissue38,39.
Neutrons undergo nuclear collisions with protons in water, generating additional charged
particles that can ionize surrounding molecules. Exposures to leakage neutrons can be
reduced by using magnetically scanned beams instead of passively scattered beams30,32,37.

NIH-PA Author Manuscript

The production of secondary neutrons in radiotherapy has been measured for different
facilities (FIG. 2b). A recent review32 shows substantial inter-centre variability: this
variation is attributed to many factors, including differences in the treatment units,
experimental techniques and reporting methods. When heavy ions are considered, the
neutron yield is caused, in part, by the fragmentation of the12C projectiles39, which is not
relevant in proton therapy. However, this effect is compensated for by the reduced number
of 12C ions necessary to deliver a given dose: approximately 1010 C ions per treatment, a
factor of 100 fewer ions than with proton therapy30.
Such estimates are affected by very large uncertainties, depending on the specific treatment,
site, quality factor and distal organ under consideration. A detailed set of dose measurements
for a patient were carried out at GSI Helmholtz Center, Darmstadt, Germany, in 2008, when
it was discovered that a young woman treated for a skull-base chordoma with12C ions was
pregnant40. Neutron and photon doses in the uterus region were monitored during the
treatment using both active and passive detectors. The dose in the pelvis for the full
treatment was 82 μSv, and neutrons contributed about 30% to the total dose. Considering the
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uncertainty, an upper limit of 0.2 mSv for the uterine dose was estimated40. Both the mother
and the child are healthy and do not have radiotherapy-related complications 3 years after
treatment.
Taken together, these data suggest that particle therapy is typically not causing an increase
in the dose to distal organs compared with high-energy IMRT. However, great care should
be taken in comparing these values, which generally refer to the effective dose41,42 (BOX
1), a controversial radiological unit. Indeed, effective doses use tissue weighting factors that
are estimated by several stochastic end points, and do not include any age- or genderdependence in cancer risk43. Especially for paediatric patients, the assumption that
weighting factors are independent of age at exposure is tenuous. Cancer is a tissue-specific
disease, and there is no evidence that the shape of the dose–response curve is the same for
different organs. The International Commission on Radiological Protection (ICRP) indeed
recognizes that the use of effective dose in medical applications may be inappropriate and it
would be more useful to calculate the risks for specific age and gender groups, using
absorbed or equivalent doses to organs and tissues and age-related risk factors44.

Mechanisms of radiation-induced carcinogenesis
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Ionizing radiation has been recognized as a carcinogenic agent by the World Health
Organization for many years45,46. Although early indications of radiation-induced cancers
came from radiologists and other radiation workers, certainly the main epidemiological
evidence of radiogenic carcinogenesis in humans and its dose–response relationship comes
from the 1945 atomic bomb (A-bomb) survivor cohort47. Leukaemia and many solid cancers
(especially lung, colon, breast and thyroid cancer) have been linked to radiation exposure46.
The risks of developing a solid tumour after radiation exposure are reasonably well
described by linear dose–response functions in the dose range from 0.2 Sv to 2 Sv (FIG. 3).
However, epidemiology does not provide the necessary information for SMNs in
radiotherapy patients, in which a small volume is exposed to high doses, and the rest of the
body to low doses. The SMN risk is then calculated using models: usually, the linear-nothreshold (LNT) assumption is adopted at low doses48, whereas models taking into account
competition between cell killing and transformation are used in the high dose region49,50.
Physical doses are converted into dose equivalents using weighting factors at low doses or
RBE values at high doses (BOX 1), and then the risk of cancer incidence or mortality is
estimated by the product of the equivalent dose and organ-, age- and gender-specific risk
coefficients, which have been mostly derived from A-bomb survivors. The models are
affected by substantial uncertainties, which can only be reduced with a better understanding
of the mechanism of radiogenic carcinogenesis31,48.
What is the molecular mechanism of radiation-induced cancer, especially of therapy-related
cancers? Although we do not have a comprehensive answer, it is well known that cancer is a
complex multistep process, and radiation can influence both initiation and promotion. DNA
damage and repair, particularly double-strand breaks (DSBs), genomic instability and
epigenetic mechanisms have key roles48. There is no evidence that mechanisms of therapyrelated cancers are different from those of sporadic cancers51, and therefore SMNs resulting
from radiotherapy would just be part of the general problem of radiation-induced
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carcinogenesis. The relative cancer risks among Japanese A-bomb survivors are generally
greater than those among comparable subsets in studies of medically exposed individuals46,
probably because of the sterilization effects at high doses and the fractionation effects52.
However, there are a few specific mechanistic issues that are particularly relevant for SMNs
in radiotherapy patients: the problem of genetic susceptibility, the possible presence of
different mechanisms at low and high doses, and the problems of split doses and radiation
quality.
Genetic susceptibility

NIH-PA Author Manuscript

Apart from lifestyle factors (such as, smoking and a poor diet), genetic susceptibility is a
major confounding factor in determining therapy-related cancers52. Can a genetic mutation
or polymorphism that is associated with the primary cancer affect the risk and the
mechanism of radiation-induced carcinogenesis? Mutations in high-frequency but lowpenetrance genes, as well as in low-frequency but high-penetrance genes, can enhance
predisposition to radiation-induced cancers. The large increased risk of contralateral second
primary breast tumours in women carrying mutations in the high-penetrance genes BRCA1
and BRCA2 provides evidence that mutations in these genes are involved in both the initial
cancer and the increased risk of development of the second breast cancer53. The other wellknown case is ataxia telangiectasia, in which the key gene ataxia telangiectasia mutated
(ATM) is also an essential signalling molecule for DNA DSB repair following exposure to
radiation, and its mutation is linked to genomic instability and cancer54.

NIH-PA Author Manuscript

How many genetic defects that are associated with the initial cancer can predispose to a
second, radiation-induced malignancy? The recently established Radiogenomics
Consortium5 will carry out genome-wide studies to identify genes that are involved in late
effects after exposure to radiation. This is certainly an ambitious programme, especially as a
single nucleotide polymorphism (SNP) could be responsible for increased sensitivity. For
patients with bilateral retinoblastoma, osteosarcoma is the most frequent SMN that is
induced by radiotherapy, which suggests that heterozygosity for the tumour suppressor gene
retinoblastoma 1 (RB1) may predispose to radiation-induced bone sarcomas. In fact, genetic
mapping in mice showed that multiple loci confer a genetic susceptibility to α-particleinduced osteosarcoma55, and Rb1-heterozygous mice have an increased risk of α-particleinduced osteosarcoma56. Interestingly, Ink4a (an upstream regulator of RB1)-heterozygous
mice did not have increased susceptibility but had reduced tumour latency after radiation
exposure56. Animal models and the whole-genome screening in radiotherapy patients are
likely to increase our knowledge of the role of genetic predisposition to SMNs.
Low doses versus high doses
One special characteristic of SMNs following radiotherapy is that they can arise either in the
irradiation field (high-dose region) or in the distal organs (low-dose region). The question is
whether different biological mechanisms may be causing low dose- and high dose-induced
carcinogenesis. The rationale behind this question is that radiation can affect both the
initiation and the promotion steps in carcinogenesis.
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In tissues exposed to low doses, the LNT for the dose–response curve is based on the
assumption that even a single electron can induce DNA DSBs that could result in an initial
carcinogenic event, even though the probability of this happening is low57. At low doses,
non-targeted effects58 may increase the cancer risk by increasing the size of the susceptible
target from one single cell to a whole tissue or a part of the tissue, although a protective
mechanism has also been hypothesized, in which damaged cells are removed from the
organism by intercellular signalling to protect tissue stability.
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In the high-dose region, ionizing radiation will effectively kill cells in the field. The
resulting tissue inflammation can promote carcinogenesis59. The response of the
microenvironment to radiation and/or oxidative stress is mediated by cytokines, including
epidermal and fibroblast growth factors, interleukins and pro-inflammatory cytokines60.
Activation of the cytokine transforming growth factor-β (TGFβ) is an early and persistent
event in tissues that have been exposed to ionizing radiation, and it can have protective or
damaging effects: for example, it can protect the stem cell compartment in the intestine, but
it can also promote invasion and metastasis in the epithelial tissue61. Although
epidemiological data clearly show that radiation-induced cancer risk is much higher for
exposure during childhood, a recent analysis of the A-bomb survivor cohort suggests that
the decrease of cancer risk with age is not continuous for exposure in adulthood62. In middle
age a number of dormant tumours might be present, so exposure to radiation could cause
tumour promotion63. Initiation is likely to be the dominant process in the exposure of young
people. Therefore, in radiotherapy for paediatric patients, the main concern would be the
low-dose exposure of distal organs, whereas for adults high-dose-induced in-field SMNs can
be expected owing to inflammation and promotion in pre-neoplastic tissue.
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Finally, are out-of-field tumours caused by only low-dose, stray radiation? A bystander
effect in vivo can be seen after exposure to high doses of radiation, known as an abscopal
effect64. Recent data have shown an increased incidence of medulloblastoma in Patched 1
(Ptch1)-heterozygous mice after high-dose (3 Gy) exposure of the lower body65, and
apoptosis of unirradiated bone marrow cells can be induced in mice exposed to 4 Gy γrays66. These high-dose, non-targeted effects are systemic effects, which are transmitted
through the nervous, immune or vascular systems, and may be long-range and significant. If
radiation at low doses (FIG. 3a) does not have an effect on — or even protect against —
cancer induction67, the non-targeted (abscopal) effect of these high target doses could be
responsible for SMNs in distal organs.
Radiation quality
Radiation quality and its influence on the carcinogenic mechanism is one of the main issues
in radiation protection. The radiation weighting factors wR, which are used to calculate the
equivalent dose (BOX 1), are among the few parameters that are not based on epidemiology
but on laboratory research studies.
So far, there is no evidence that radiation carcinogenesis is based on different mechanisms
for different radiation qualities31. Although high-LET radiation induces complex damage
measured both at the DNA68,69 and the chromosomal70 levels, complex DNA lesions can
also be induced by low-LET electrons and are often considered the crucial lesions that lead
Nat Rev Cancer. Author manuscript; available in PMC 2014 July 17.

Newhauser and Durante

Page 9

NIH-PA Author Manuscript

to late cellular consequences. Non-targeted effects are particularly important in the case of
low-fluence high-LET (that is, a low number of particles each delivering a relatively high
dose) radiation71, but as noted above it is still unclear how much non-targeted effects
contribute to radiation carcinogenesis. Gene expression profiles are often very different
following exposure to different radiation qualities72, and the same is observed switching
from low doses to high doses73, but gene expression following radiation or any other
mutagenic stressor is a complex, time-dependent phenomenon, and difficult to use as a
biomarker of late end points such as SMNs.
Protons

NIH-PA Author Manuscript

For estimating cancer risk from protons, we must rely entirely on animal and cellular
experiments. The US Air Force and NASA carried out one such study from 1963 to 1969
(REF. 74). About 2,000 rhesus monkeys and 5,000 mice were irradiated with protons of
energies ranging from 32 MeV to 2,300 MeV obtained using cyclotrons at various
institutions. Exposures to electrons and X-rays were also carried out to enable the
comparison of the effects of radiation of different qualities. The RBE for protons for acute
mortality was about 1.0 to 1.1, which is the RBE generally used in human therapy75. The
dose–response relationships that could be derived were curvilinear and consistent with those
found in other experimental studies of the effects of low-LET radiation. In female monkeys,
endometriosis was a major radiation effect that contributed to a shortened lifespan74.
Another notable finding was the increased incidence of malignant brain tumours in the
monkeys exposed to 55 MeV protons. In rodent systems, 250 MeV protons have been
shown to be slightly more effective than γ-rays for the induction of Harderian gland76 or
mammary77 tumours. However, these data are insufficient to provide an estimate of the RBE
for cancer induction at the different proton energies.
Neutrons

NIH-PA Author Manuscript

The maximum RBE values for neutrons are observed at low-dose rates, especially for those
end points for which a pronounced sparing effect is observed with low-LET radiation. The
estimates of neutron relative effectiveness are mostly based on animal studies (FIG. 3b),
although A-bomb survivors were also exposed to neutrons. In an extensive series of studies
at the French Alternative Energies and Atomic Energy Commission (CEA) on male rats, a
fission-neutron dose of 20 mGy was found to be equivalent to 1 Gy of acute γ-rays to induce
both lethal and non-lethal tumours78. Another large database is available from the JANUS
programme at the Argonne National Laboratory. In approximately 32,000 mice with acute
and fractionated exposures to γ-rays or neutrons79, RBE ranged from 2 to 50 and increased
with dose fractionation. In these mice, tumours of epithelial tissue were induced by the
highest RBE values and tumours of connective tissue origin were induced by the lowest
RBE values. Limited data from monkeys on the effects of high-dose total body irradiation
showed that the relative risk (that is, the cancer mortality rate relative to mortality rate in
unirradiated controls) was approximately 8 for the X-irradiated group and 14 for the
neutron-irradiated group80.
Although RBE for fission-spectrum neutrons has been measured in many experimental
systems, less data are available for high-energy neutrons, which are produced in particle
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therapy30 (FIG. 2b) and in spacecraft31. A recent experiment in Medaka fish embryos
exposed to a high-energy neutron source at the Los Alamos Neutron Science Center reported
an RBE ranging between 25 and 48 relative to γ-rays for apoptosis in cells of the developing
brain81.
Heavy ions

NIH-PA Author Manuscript

Finally, for heavy ions we have probably the highest uncertainty in terms of predicting late
effects in humans31. Although it is generally assumed that the RBE increases with LET
values around 100–200 keV per μm and then decreases at higher values, it depends on
several factors, including the tumour type. The RBE of 1 GeV per nucleon 56Fe ions for
inducing cancer in mice was around 1 for leukaemia (FIG. 3b) but more than 40 for
hepatocellular carcinoma82. How can the RBE be so different? The reason is probably due
to the different nature of haematological and solid cancers. For haematological cancers
radiation could act as an initiator, but for solid cancers (especially those strongly linked to
inflammation, such as liver cancer) it could act mainly as a promoter. Although heavy ions
are more effective than X-rays in the induction of chromosomal rearrangements, most of the
aberrations are lethal, and the RBE for chromosome aberrations drops to about 1 in the
surviving cell population70. Conversely, heavy ions are effective in the induction of
inflammation83. In general, only the organs in the beam path are exposed to heavy ions,
while distal organs receive neutrons and scattered protons, indicating that SMNs in heavyion therapy could be most relevant to adult patients.
Fractionation

NIH-PA Author Manuscript

A further complication in radiotherapy is caused by an incomplete knowledge of the
biological effects of dose fractionation. In classical radiobiology textbooks it is stated that
the same dose delivered at a low dose rate or in daily fractions is less effective than acute
exposure (sparing effect), but the extrapolation from high- to low-dose rate is one of the
main sources of uncertainty in radiogenic cancer risk estimates84. In a recent, careful review
of available experimental data (including human, animal and in vitro data) on radiation
carcinogenesis, Suit et al.85 concluded that fractionation does not necessarily lead to a
reduced cancer risk. As some SMNs could be caused by exposure to low-dose neutrons, it
should also be noted that some in vitro data suggested that an inverse dose-rate effect exists
for neutrons — carcinogenesis would be enhanced at a low-dose rate compared with acute
exposure to fission-spectrum neutrons86. The inverse dose-rate effect is controversial, it has
not been confirmed in subsequent experiments, and it might be visible and relevant only in a
small window of dose rates, doses and LET87. The issue of carcinogenicity of split doses
also remains unclear both in high- and low-dose regions, and more experiments to clarify
this issue are urgently needed.

Estimates of radiotherapy-related risk of SMNs
Contemporary SMN risk models typically take into account various host-related factors that
influence predicted risk, including age at exposure, attained age and sex62. Typically, risks
are larger for females, decrease with age at exposure and continue to increase with attained
age decades after exposure88. The subpopulation of patients who are at the greatest risk for
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the development of SMNs would potentially benefit the most by adding modifying factors to
the risk models to take into account lifestyle choices, occupational exposures and genetic
variation.
To accurately predict radiogenic risk using the models described above, the radiation doses
in the tumour, as well as in healthy tissues and organs throughout the entire body, must be
calculated. Fortunately, this is now possible, thanks to strident progress in radiation transport
models, nuclear interaction data and models, and high-performance computing14. This
means that, in principle, we can now calculate the dose to the patient and transform it to a
cancer-risk map in the body (FIG. 4). In fact, our understanding of the physics of particle
therapy is advanced and nearly complete for the purposes of SMN risk assessment. Most of
the uncertainty remains in the biology (TABLE 1): we can calculate an organ dose fairly
accurately, but the translation of the physical dose into an equivalent dose (BOX 1) and then
to an organ-specific risk for cancer incidence and mortality is affected by large uncertainties
that are caused by the uncertainties in weighting factors and cancer risk factors. The risk
estimates in FIG. 4 are therefore only qualitative, but the calculation with the colour scale
clearly shows how the dose is a poor predictor of risk, and large organ-specific differences
can be found between incidence and mortality risks.
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Studies comparing SMN risks that are associated with contemporary proton and photon
therapies have consistently found that proton therapy confers smaller overall predicted risk
of SMNs for children with medulloblastoma89,90 and for adults with prostate cancer91 and
liver cancer92. The models found a negligible difference between lifetime risk of SMN
incidence from passive versus scanned proton craniospinal irradiation: the risk was mostly
attributable to therapeutic radiation, not leakage neutrons93–95. Similar findings were
obtained for several patients treated for prostate cancer91,96. Perhaps the most important
findings, however, are from comparative studies of passively scattered proton therapy and
photon IMRT. These studies revealed that the largest reductions in predicted risk were
obtained by replacing IMRT with proton therapy91, even after taking into account the stray
and leakage neutrons that are associated with proton therapy. In fact, these findings were
significant even when taking into account the large uncertainties in neutron RBE values
(FIG. 2c) for carcinogenesis90.
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New challenges
The problem of SMNs in paediatric radiotherapy patients is technically complex and
challenging. There is good epidemiological evidence that radiation therapy is making a
crucial contribution to long-term survival of childhood cancers, but it is also causing a high
incidence of SMNs among survivors of childhood cancer. Given the size and consequences
of this problem, it is vital that we meet our obligation to ensure that any avoidable and
detrimental exposures to radiation are as low as can be reasonably achievable. However, it
will be challenging to precisely define a reasonably low level of exposure in terms of risk/
benefit, and difficult to predict how much can be reasonably achieved with finite effort and
expense97.
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Fortunately, there are several avenues of research available to reduce SMN risks from
particle radiotherapy. Modifying treatment units to reduce stray radiation is an obvious and
attractive approach32. This can be accomplished by reducing the production of stray
radiation inside the treatment unit and by increasing its attenuation with additional local
shielding. For example, simple enhancements to a passively scattered proton nozzle
(shielding) and treatment technique (distance) reduced the dose to paediatric patients by up
to 40–50%95. New research studies are needed to strengthen the initial evidence used to
design personalized treatment strategies, such as the selection of radiation type that is likely
to have the least detrimental effects, and treatment techniques, such as beam angles. The
long latency times for SMNs require that research uses computational approaches to develop
risk mitigation strategies, supplemented with radiobiological and radioepidemiological data
as they become available.
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Moreover, we should compare the stray therapeutic radiation with the dose from diagnostic
procedures, which is rapidly increasing and causing concern for long-term risk in the
population98,99. In most cases imaging during therapy accounts for less than 20% of the
stray therapeutic radiation, but with the extensive applications of IGRT with daily portal
imaging or cone-beam CT using MV X-rays, whole-body exposures of up to 100 mGy per
day are possible, thus exceeding those caused by the scatter radiation from the therapeutic
beam100. When possible, orthogonal pairs of images with kV X-rays should be used to
reduce the dose, considering that for paediatric patients the dose to important structures from
kV cone-beam CT can be twofold to threefold higher than for adults101
The main research issues for SMNs in distal organs and for those in the radiation field for
paediatric patients are summarized in TABLE 1. In both high- and low-dose regions, the
shape of the dose–response curve and its dependence on fractionation for carcinogenesis
should be determined: this is clearly organ-specific, and it is therefore important to collect
information about organ doses received during therapy. Even that could not be enough, as in
some cases only a part of an organ is exposed to a high dose, and the other part to a low
dose. How to deal with such a non-uniform exposure remains an open problem for late
effects.
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Despite the large uncertainties, data collected so far suggest that particle therapy should lead
to a lower risk of SMNs than conventional X-ray techniques102. This is mainly attributed to
lower doses to healthy tissues from the therapeutic beam and to the relatively low risk
associated with neutron exposures to the whole body, especially with the spot-scanning
delivery method. In other words, less normal tissue is exposed and distal organs receive
lower stray radiation. This should also apply to heavy ion therapy, in which the therapeutic
dose to healthy tissues is again very low and neutron production even lower than for
protons, as fewer particles are needed to achieve the same target dose30. In fact, a lower
yield of chromosomal aberrations is measured in the peripheral blood lymphocytes of
patients treated with C ions compared with X-rays for the same cancers103,104. Some
concerns may arise in the moderate–high dose regions, in which particles can be more
effective in inflammation and promotion, although this mechanism may be more relevant for
adult patients than for paediatric patients.
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Medulloblastoma

Malignant primary brain tumour that originates in the cerebellum
or posterior fossa.

Atomic bomb
survivors database

Survivors of the atomic bombs dropped in 1945 in Japan have
been followed for cancers for more than 60 years, and represent
the main source of epidemiological data on radiogenic cancers.

Stray radiation

Therapeutic beam radiation that is emitted through the accelerator
housing and reaches the patient outside of the treatment volume.

Radiation quality

Ionizing radiation includes many different qualities: high-energy
electromagnetic radiation (such as X-rays), neutrons, electrons,
protons and heavy ions. Their different biological effectiveness is
scaled using weighting factors (BOX 1).

Relative biological
effectiveness

The ratio of the dose, DR, of a reference radiation (typically γ-ray
or X-rays) and Dt of a test radiation (for example, neutrons,
protons and heavy ions) that produce the same biological effect.
It depends on several factors including the dose, dose rate,
biological end point, radiation test LET and tissue.

α-particles

Helium nuclei emitted by some heavy elements by a natural
radioactive process known as α-decay. They represent the highLET component of the natural radiation background for the
general population, mostly caused by inhalation of Radon gas.

Intensity-modulated
radiation therapy

Currently the most advanced type of photon radiotherapy.
Accurate conformation to the target tumour is achieved by
increasing the intensity of the rays to the target, and reducing the
intensity of the beams that cross sensitive structures. The
resulting inhomogenous dose distribution in the single field is
compensated by cold and hot spots in the beams coming from
other directions.

Monitor units

A monitor unit (MU) is a measure of the linear accelerator
(Linac) output. The dose to the target is calibrated with a detector
(monitor), and therefore MUs correspond to a given dose to the
tumour.

Bragg peak

Region where charged particles release most of their energy in
matter, before stopping.
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Passive proton beam
shaping

A technique that spreads the Bragg peak, using attenuators and
collimators.

Magnetically
scanned beams

Also known as spot scanning, a technique to deliver particle
therapy. A small pencil beam is deflected by a magnet in two
dimensions to cover a slice of the tumour, and the next slice is
exposed by changing the energy in the accelerator. Unlike
passive beam shaping, it does not require attenuators to modulate
the Bragg peak, and therefore the production of neutrons outside
the patient’s body is negligible.

Linear-no-threshold

The model commonly adopted by the International Regulatory
Agencies to extrapolate the radiation risk at low doses. It is
assumed that the cancer risk is always directly proportional to the
absorbed dose.

Sterilization effects

At high radiation doses, the cell killing (sterilization) overcomes
the radiation transforming potential, and hence the neoplastic
transformation per exposed cell decreases.

Fractionation

The therapeutic radiation dose is very high (up to 60–70 Gy), but
is normally delivered in daily fractions of approximately 2 Gy for
effective sparing of the normal tissue.

Ataxia telangectasia

A rare and severe neurodegenerative disease (also known as
Boder–Sedgwick or Louis–Bar syndrome). It is caused by a
defect in ATM, which encodes a serine/threonine protein kinase
involved in DNA repair and cell cycle regulation.

Non-targeted effects

Radiation effect observed in cells, tissue or organs not directly
exposed to radiation. It can be caused by cell-to-cell
communication via gap junctions, release of cytokines in the
body, or mediated by the immune or nervous system.

Bystander effect

A non-targeted effect generally observed in cellular experiments.
The ‘bystander’ cell can receive radiation damage, although only
the neighbouring target cell is exposed.

Abscopal effect

A radiation response in an organ not directly exposed to the
radiation field.

Harderian gland

A subcutaneous accessory lacrimal gland found within the eye’s
orbit in many vertebrates (not in humans).

Sparing effect

When the same radiation dose is delivered in multiple fractions,
at intervals of several hours (typically 1 day), the biological
damage is generally reduced.
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Fission-spectrum
neutrons

Neutrons produced during the nuclear fission process, typically in
nuclear reactors for energy production. The energy spectrum
peaks at about 1 MeV.
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Box 1
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Radiation dose
Absorbed dose
Absorbed dose (or dose) is the energy deposited per unit mass in the target: D = ΔE/ΔD
This is measured in gray (Gy). 1 Gy = 1 J per kg.
Equivalent dose
The equivalent dose (or radiation-weighted dose) takes into account the different
, in which DT,R
biological effectiveness of different radiation qualities.
is the absorbed dose (in Gy) averaged over the tissue or organ (T) owing to radiation (R).
H is measured in sievert (Sv).
The weighting factors (wR) are estimated by relative biological effectiveness (RBE)
values at low doses and low dose rates, and they are therefore useful for radiation
protection at low doses, but not for protection from deterministic effects at high doses. In
this case, the International Commission on Radiological Protection (ICRP) recommends
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, in which the the
a different definition of the equivalent dose:
weighting factors are replaced with RBE values, which are radiation (R)- and end point
(e)-specific. The unit is the gray-equivalent (GyE).
Effective dose
For non-uniform exposure to radiation, different tissue weighting factors wT have to be
used that reflect the different radiogenic sensitivity of the different organs. The effective
dose (also in Sv) is then calculated as:
RBE-weighted absorbed dose
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In particle therapy, owing to the use of high doses, the GyE has been used for heavy ions,
while the proton therapy community still uses the cobalt gray equivalent (CGE), which
refers to a dose that is clinically isoeffective to60Co γ-rays, formerly the most commonly
used radiation in teletherapy. The International Commission on Radiation Units and
Measurements (ICRU) has recently proposed41 to replace this quantity with the RBEweighted absorbed dose defined as: DRBE,V = RBE · DV
The unit will be again the gray but written as Gy(RBE). The volume V (for example,
gross tumour volume or planning target volume) must be specified.
Integral dose
Also important for comparing different radiotherapy modalities is the concept of integral
dose, defined as the mean energy deposited in the total irradiated volume of the patient
(in kg × Gy): ID = m · D
Isoeffective dose
In an effort to unify the RBE-weighted absorbed dose and the biologically effective dose,
a joint IAEA and ICRU commission42 proposed another quantity indicated as
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isoeffective dose and defined as DisoE = WisoE · D, in which D is the absorbed dose in Gy
and WisoE an inclusive weighting factor that takes into account all factors that could
influence the clinical effects: dose per fraction, overall time, radiation quality, biological
system and effects. The reference treatment conditions for estimating WisoE are X-rays, 2
Gy per fraction and 5 daily fractions per week. As for DRBE, the applications of DisoE in
heavy-ion therapy is problematic owing to the complex RBE field.
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•

The availability of high-energy beams of photons, protons and carbon ions has
contributed to increases in tumour control and the sparing of normal tissues
from acute radiation toxicity.

•

Advances in cancer therapies for children have produced impressive prospects
for long-term survival. Approximately 80% of children and adolescents treated
for cancer survive more than 5 years, but roughly 73% of them develop
treatment-related complications. The complication of perhaps greatest concern
is the risk for developing a radiogenic second malignant neoplasm (SMN),
which can develop years or decades after treatment.

•

Although the patient receives a high dose of therapeutic radiation, which is
focused at the diseased tissue, the entire body is exposed to comparatively low
doses of unwanted radiation that are caused by radiation leaking from the
treatment apparatus and by scattering of the therapeutic radiation within the
body.

•

Mechanisms of therapy-related cancers are similar to those of sporadic
tumorigenesis, but the carcinogenic potential of low doses of photons is not
completely understood, and the uncertainty is much higher for cancer that is
induced by charged particles.

•

Epidemiological studies have conclusively shown that some SMNs can develop
in tissues that are located in-field (that is, in the path of the therapeutic beam)
and out-of-field (outside the path of the therapeutic beam).

•

Recent models predict that particle therapy lowers the risk of SMNs compared
with contemporary photon therapies.

•

Regardless of the type of radiation beams used, nascent approaches to
personalized, risk-adapted radiotherapy seem to be likely to yield further
reductions in risk from out-of-field exposures, and research in genetic
susceptibility and radiobiology should help to identify biomarkers of long-term
risk in cancer survivors.
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Figure 1. Treatment planning
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Examples of treatment plans for craniospinal irradiation using photon (part a) or proton
(parts b and c) beams. The dose levels are shown as semi-transparent colour, superimposed
on axial images of the patient from a computerized tomography scan. In the X-ray treatment
(part a), the therapeutic radiation is highly localized laterally to the region of diseased tissue.
Healthy tissues such as the heart and thyroid are in the beam path and receive large exit
doses. For passive-scattered proton beams the therapeutic radiation (part b) is highly
localized to the diseased tissues, whereas the comparatively low doses of leakage neutrons
(part c) irradiate the entire body. Treatment plans for prostate radiotherapy are shown in
parts d and e, with intensity-modulated radiation therapy (part d; seven coplanar fields) and
a 12C ion plan (part e; two fields). Shown in greyscale is the computerized tomogram
overlaid by the prescribed dose percentage in colour. The thick contour in black represents
the clinical target volume, the dashed contour the gross tumour volume, and in thinner
contours the rectum and the femoral head, which are tissues that are at risk from radiation.
Parts a, b and c are from the M.D. Anderson Cancer Center. Parts d and e are courtesy of A.
Nikoghosyan and J. Debus, Heidelberg University Hospital, Germany.
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Figure 2. Secondary neutron dose in particle therapy
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a ∣ Schematic diagram of a spinal treatment field in particle therapy. A small diameter beam
of charged particles (red) enters the treatment apparatus, which spreads the beam to a
clinically useful size and collimates it to spare healthy tissues. Stray neutron radiation
(green) is created by proton-induced nuclear reactions in the treatment unit and in the
patient. The neutron doses provide no therapeutic benefit but increase the predicted risk that
a patient will develop a second cancer later in life as a result of radiation exposure. b ∣ The
energy spectrum of photoneutrons produced by megavoltage X-rays and secondary neutrons
produced by nuclear interactions of charged particles is complex. The figure shows recent
neutron spectral measurements at the ELEKTA Linac accelerator in the Klinikum Goethe
Universität of Frankfurt, Germany, operated at 25 MV, and at GSI, Darmstadt, Germany,
with a 200 MeV per nucleon 12C pencil beam stopping in a water target. The energy in MeV
is on the x axis in log-scale, whereas the y axis gives the number of neutrons counted per
unit solid angle (in millisteradiants (msr)) and per unit dose (in Gy) to the target.
Photoneutrons were measured at 10 cm or 40 cm from the target area. Secondary neutrons
produced by the 12C ions were measured at two angles from the beam path (for details of the
measurements see REF. 38). The yield of neutrons decreases by increasing the distance from
the target or the scattering angle, but clearly X-rays produce mostly neutrons around 1 MeV,
and particle therapy neutrons with energies around 100 MeV. These different spectra result
in different (organ-specific) risk factors. c ∣ Neutron radiation weighting factor wR (BOX 1)
is shown as a function of the neutron energy according to the latest International
Commission of Radiological Protection recommendation44. The most effective neutrons are
considered to be those with energies around 1 MeV. Part b courtesy of C. La Tessa, GSI,
Darmstadt, Germany.

Nat Rev Cancer. Author manuscript; available in PMC 2014 July 17.

Newhauser and Durante

Page 25

NIH-PA Author Manuscript

Figure 3. Dose–response curve for carcinogenesis
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a ∣ Epidemiological data in humans are mostly derived from atomic bomb (A-bomb)
survivors in the dose range 0.1–2.5 Sv. At lower doses, The International Commission on
Radiological Protection (ICRP)44 recommends a linear extrapolation (the linear-nothreshold (LNT) model). However, the non-targeted (bystander) effect or the existence of
radiosensitive subpopulations may suggest that the LNT model underestimates the risk58.
Conversely, an adaptive response would imply that the LNT is overestimating the risk66.
Ongoing research has not yet clarified the importance of these mechanisms in low-dose
carcinogenesis48. Similarly, the extrapolation at high doses, relevant for the risk of in-field
second malignant neoplasms (SMNs), is uncertain. The risk may decrease owing to cell
killing (as suggested for second thyroid cancer in the Childhood Cancer Survivor Study
(CCSS) study19), remain linear (as it seems for central nervous system SMNs in the CCSS
database19) or plateau (as suggested by second lung and breast cancers in survivors of
Hodgkin’s lymphoma50). Cellular repopulation during and after the therapeutic radiation
exposure may in fact counteract cell killing at high doses. b ∣ An example of dose–response
curves for the induction of cancer in animal models by radiation of different qualities. Acute
myeloid leukaemia (AML) in CBA mice exposed to γ-rays, fission neutrons or 1 GeV per
nucleon 56Fe ions. The relative biological effectiveness (RBE) is about 3 for neutrons and 1
for heavy ions. However, the RBE values depend on the genetic strain, tumour type and
fractionation used. The curves represent guides drawn by eye from data points in REFS
82,105. Part a courtesy of E. J. Hall, Columbia University, USA.
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Figure 4. Dose and risk distribution for second cancer

A 9-year-old girl received craniospinal irradiation for medulloblastoma using passively
scattered proton beams at the M.D. Anderson Cancer Center, USA. The colour scale
illustrates the difference for absorbed dose, incidence and mortality cancer risk in different
organs. Radiation absorbed dose depends strongly on patient anatomy and treatment factors.
Risk of second malignant neoplasm (SMN) incidence and mortality varies strongly with
radiation dose, but, importantly, it also varies strongly between organs, the age of the patient
at exposure and the attained age, sex and genetic profile, as well as other factors.
Consequently, as this figure illustrates, dose is a poor biomarker for SMN risk. In future,
novel risk visualization and analysis methods will be needed to facilitate routine riskadapted, personalized clinical decision making.
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Key questions in paediatric SMN research using modern radiotherapy techniques
Main research problems

In-field, moderate to high doses
of X-rays, protons or heavy ions

Out-of-field, low doses of photons,
neutrons or scattered protons

Knowledge of organ and tissue doses

Accurate

Large uncertainties, limited availability
of capability to calculate doses

Organ-specific shape of the
dose–response curve for carcinogenesis

X-rays and charged particles at
moderate to high doses

Therapy-like neutron spectra and
mixed fields at low doses

Effect of fractionation

Low- and high-LET radiation at high
doses

Split doses of neutrons: inverse
dose-rate effect?

Genetic susceptibility

For cancer promotion by
inflammation

For cancer induction (initiation)

Non-targeted effects

In tissue surrounding the PTV

Abscopal or tissue-mediated effects in
distal organs

LET, linear energy transfer; PTV, planning target volume; SMN, second malignant neoplasm.
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